- Home
- RUM vs TSHA Comparison
RUM vs TSHA Comparison
Compare RUM & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RUM | TSHA |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RUM | TSHA |
|---|---|---|
| Price | $9.50 | $5.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.63 |
| AVG Volume (30 Days) | ★ 4.0M | 2.4M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.72 | 5.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $100,622,320.00 | $9,773,000.00 |
| Revenue This Year | $209.98 | N/A |
| Revenue Next Year | $40.99 | $1,152.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 5.38 | ★ 17.28 |
| 52 Week Low | $4.62 | $2.72 |
| 52 Week High | $10.60 | $7.30 |
Technical Indicators
Market Signals| Indicator | RUM | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 70.60 | 48.03 |
| Support Level | $5.37 | $5.28 |
| Resistance Level | $10.54 | $6.68 |
| Average True Range (ATR) | 0.75 | 0.33 |
| MACD | 0.24 | -0.03 |
| Stochastic Oscillator | 76.92 | 28.92 |
Price Performance
Historical ComparisonAbout RUM Rumble Inc.
RUM Group Inc focused is to maximize the power of human imagination through an independent technology ecosystem built on privacy, resilience, and an open alternative to Big Tech. Rumble gives human creativity a voice, a video and media platform built for creators and audiences who value free expression. Quake AI is a cloud and AI-infrastructure business, delivering the compute, data-center capacity, and blockchain infrastructure for the agentic era.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.